Drug Profile
PF 5297909
Alternative Names: PF-05297909; PF-5297909Latest Information Update: 16 May 2012
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antidementias; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 10 May 2012 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
- 29 Feb 2012 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT01462851)
- 27 Oct 2011 Phase-I clinical trials in Alzheimer's disease (healthy volunteers) in USA (PO)